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ABSTRACT  
 
Background: Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic 
kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the 
Handling Erythropoietin Resistance with Oxpentifylline (HERO) multi-centre double-blind, 
randomized controlled trial. The present sub-study evaluated the effects of pentoxifylline on the iron-
regulatory hormone hepcidin in ESA-hyporesponsive CKD patients. 
Methods: This sub-study included 13 patients in the pentoxifylline arm (400 mg daily) and 13 in the 
matched placebo arm. Hepcidin-25 was measured by Ultra Performance Liquid 
Chromatography/Quadrupole time-of-flight mass spectrometry following isolation from patient 
serum. Serum hepcidin-25, serum iron biomarkers, haemoglobin and ESA dosage were compared 
within and between the two groups.  
Results: Hepcidin-25 concentration at 4 months adjusted for baseline did not differ significantly in 
pentoxifylline vs. placebo treated patients (adjusted mean difference (MD) -7.9nmol, P = 0.114), 
although the difference between the groups mean translated into a >25% reduction of circulating 
hepcidin-25 due to pentoxifylline compared to the placebo baseline. In paired analysis serum 
hepcidin-25 levels were significantly decreased at 4 months compared to baseline in the pentoxifylline 
group (-5.47±2.27nmol/l, P<0.05), but not in the placebo group (2.82±4.29nmol/l, P=0.24). 
Pentoxifylline did not significantly alter serum ferritin (MD 55.4mcg/l), transferrin saturation (MD 
4.04%), the dosage of ESA (MD -9.93 U/kg/week), or haemoglobin concentration (MD 5.75g/l). 
Conclusions: The reduction of circulating hepcidin-25 due to pentoxifylline did not reach statistical 
significance, however, the magnitude of the difference suggests that pentoxifylline may be a clinically 




Erythropoiesis stimulating agents, anaemia, chronic kidney disease, hepcidin-25, randomised 
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INTRODUCTION 
 
The introduction of erythropoiesis stimulating agents (ESA) has resulted in a substantial reduction in 
blood transfusion requirements in chronic kidney disease (CKD) patients 
1
. Unfortunately, 7-14% of 
all end-stage kidney disease (ESKD) patients show a suboptimal hematologic response to ESA (Hb 
concentration <100 g/L) 
2, 3
. There are several known causes of suboptimal response to ESA, 
including female gender, lower body mass index 
4
, inadequate dialysis 
4
, older age 
5
, diabetes mellitus 
6




, and iron (Fe) deficiency 
4, 9
. The latter suggest that 
anaemia of CKD not only results from deficient production of erythropoietin, but also from reduced 
Fe absorption and availability for erythropoiesis. Reduced Fe absorption is likely the consequence of 
excessive production of the Fe regulatory hormone hepcidin 
10-12
, possibly in response to elevated 
interleukin 6 (IL6) or other pro-inflammatory cytokines produced in CKD.  
 
In CKD, hepcidin-25, -22 and -20 levels are elevated and the latter two isoforms of hepcidin increase 
with declining renal function 
13
. Hepcidin levels in CKD are likely to be influenced by a number of 
additional factors, especially exogenously administered ESAs and Fe therapy. Inflammation (elevated 
IL6 and IL1β), Fe therapy and relative erythropoietin deficiency will increase hepcidin levels; 
however, erythropoietin therapy, reduced Fe stores, hypoxia and anaemia are likely to have a negative 
effect on hepcidin levels 
14
. Interestingly, erythropoietin and Fe are both administered to treat anaemia 
of CKD but oppose each other’s actions on hepcidin production. In a non-randomised, non-placebo-
controlled trial, we have previously shown that administration of pentoxifylline to anaemic CKD 
patients resulted in significantly reduced serum IL6 levels, increased haemoglobin (Hb) levels and 
greater Fe mobilisation 
15
. It is highly likely that these effects are mediated via a reduction in serum 
hepcidin levels. Thus, pentoxifylline might be a novel agent for improvement of Fe bioavailability or 
reduction of total Fe dose requirement in the therapy of anaemia complicating CKD. ESA treatment 
targeting high haemoglobin levels in people with CKD is associated with increased risks of stroke, 
vascular access thrombosis and hypertension without any reduction in cardiovascular events 
16
 and 
poor response to ESA treatment is believed to be the major driver of the observed adverse outcomes 
in CKD 
17, 18





The Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial evaluated the effect of 
pentoxifylline on erythropoiesis resistance index (ERI) in patients with advanced CKD and primary 
ESA-hyporesponsive anaemia 
20, 21
. Its sentinel findings were that pentoxifylline safely increased 
haemoglobin concentration in patients with ESA-hyporesponsive anaemia, but did not significantly 
modify ESA resistance. In this pre-specified secondary analysis of the HERO Study, the role of 
hepcidin-25 in primary resistance to ESA was evaluated.  
 





Details of the HERO Study protocol and population are described elsewhere 
20, 21
. In brief, the HERO 
Study (registration number Australian New Zealand Clinical Trials Registry 12608000199314) was a 
multi-centre, double-blind, randomized placebo-controlled trial to study the effect of pentoxifylline on 
ERI. The trial included adult patients with stage 4 or 5 CKD (including dialysis patients) on a stable 
dose of either erythropoietin or darbopoetin for at least 8 weeks who had ESA-hyporesponsive 
anaemia for which there was no identifiable cause (such as iron deficiency, bleeding, inadequate 
dialysis, hyperparathyroidism, malignancy, or haematological disorder). ESA-hyporesponsive 
anaemia was defined as a haemoglobin concentration ≤120 g/l and an ESA resistance index (ERI; 
calculated as weight-adjusted weekly ESA dose divided by haemoglobin concentration) ≥1 
IU/kg/week/g/l for erythropoietin-treated patients and ≥0.005 μg/kg/week/g/l for darbopoetin-treated 
patients 
22
. Participants were randomized in a 1:1 ratio across three variables (study site, CKD stage, 
and ESA class) to pentoxifylline (Trental®, Sanofi-Aventis, Sydney, Australia) 400 mg daily orally, 
according to manufacturer recommendations in patients with reduced kidney function, or identical 
matching placebo for a period of 4 months. All other management, including iron supplementation, 
was provided according to local unit protocols. Of the 53 participants in the HERO trial (26 
pentoxifylline, 27 control), 26 consented to participate in the hepcidin-25 sub-study (13 
pentoxifylline, 13 control). Plasma concentrations of hepcidin-25 were measured at baseline and 4 
months and were compared with changes in the outcome variables (particularly serum iron markers 
and haemoglobin level). The sampling and handling of specimen for hepcidin-25 levels required 
collection of a blood sample that had to be rapidly spun and stored at -20
o
C until shipping of the 
frozen samples in dry ice was arranged. Not every participating centre was willing to accept this 
burden and therefore not all patients included in the main study participated in the substudy. 
 
Hepcidin-25 assay 
Hepcidin-25 was measured using a highly sensitive and accurate hepcidin-25 assay in humans 
23, 24
. 




N3-human hepcidin internal standard (Peptides International, Inc., Kentucky, USA) was added 
to each sample to correct for recovery and quantitation. Analysis was achieved by UPLC/QTOFMS. 
Chromatography was by a Waters Acquity liquid chromatograph (Waters, Milford MA) equipped 
with an Aeris WIDEPORE 3.6µ XB C18 column (Phenomenex Inc.) using mobile phases A; 0.2% 
formic acid and B; acetonitrile (0.2% formic acid) at a flow rate of 500 µl min
-1
. The flow was 
equilibrated at 10% B, ramped to 15% B over the first minute, and 15-40% B over the subsequent 
four minutes. Mass spectrometry was achieved with a Waters Synapt G2S (Waters, Milford MA). The 
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ion source was operated in positive electrospray ionisation mode with a cone voltage of 30 V and 
temperature of 450 °C. The desolvation gas flow and temperature were at 1,000 L hr
-1
and 450 °C, 
respectively MS data were collected at a resolution of 18,000. Mass accuracy was maintained by 
infusion of leucine encephalin lockmass reference. Quantitation was performed by calculation of peak 
area, with an ion extraction window of 0.05 Dalton using Quanlynx (Waters, Milford MA). All 
samples were measured randomised within a single analytical sequence. 
 
Statistical analysis 
This secondary analysis included only the baseline data from the main HERO Study and hepcidin-25 
sub-study. Results were expressed as frequencies (percentages) for categorical variables, 
meanstandard deviation (SD) for continuous normally distributed variables and median [interquartile 
range] for continuous non-normally distributed variables. All outcomes were analysed in accordance 
with the intention-to-treat principle. Treatment groups were compared on plasma levels of hepcidin-
25 and other outcomes at 4 months, adjusted for baseline values of each outcome of interest, using 
analysis of covariance. Associations between baseline measurements of hepcidin-25 and changes in 
haemoglobin and ERI were assessed using a Pearson’s correlation test. P values <0.05 were 






The demographics and baseline characteristics of the hepcidin-25 sub-study participants were 
comparable between the pentoxifylline and control groups (Table 1) and were comparable with those 
of the main HERO trial study groups. Similarly, ESA dose, ERI, levels of hepcidin-25 and the 
haematological parameters did not differ between the two groups at baseline (Table 2). Two patients 
in each treatment group were on parenteral iron and one from placebo was taking folate. None of the 
patients were on oral iron or any form of B12 intake. Although it is known that pentoxifylline is 
capable of modifying the cytokine production 
25
, circulating IL-6 and TNF-alpha levels were not 
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Hepcidin-25 levels 
At the end of the 4-month study period, baseline adjusted mean plasma hepcidin-25 tended to be 
lower in the pentoxifylline group compared with controls (adjusted mean difference   
-7.92nmol/l, 95% CI: -17.9 to 2.04, P = 0.114; Table 3). However, this difference was not statistically 
significant (Table 2). Changes in plasma hepcidin-25 from baseline to month 4 in the pentoxifylline 
and control groups are shown in Figure 1. There was a significant difference in hepcidin-25 at 4 
months compared to baseline in the pentoxifylline group (-5.47±2.27nmol/l, P<0.05), but not in the 
placebo group (2.82±4.29nmol/l, P=0.24). The results did not differ when the one patient with CKD 
not on dialysis was removed from the placebo group. Three patients showed a significant elevation of 
hepcidin-25 levels at Month 4, none had over signs of inflammation or infection or elevated 
circulating iron levels that could explain this increase. 
 
Erythopoietic outcomes 
There was no significant difference in haemoglobin concentration at the end of the 4-month study 
period in the pentoxifylline group compared with controls (adjusted mean difference 5.7g/l, 95% CI: -
2.51 to 14.0, P=0.114; Table 3). No significant differences were observed between the two groups 
with respect to ERI, ESA dose, serum ferritin, serum transferrin saturation, or reticulocyte count after 
adjustment for their baseline levels (Table 3). Again, the results did not differ when the one patient 
with CKD not on dialysis was removed from the placebo group. 
Although there was substantial intra-individual variability in serum hepcidin-25 (4.77 to 67.33nmol/l), 
baseline hepcidin-25 levels only showed a positive correlation with baseline ferritin levels (R2 0.579, 





This pre-specified sub-study of the HERO Study showed that oral administration of pentoxifylline in 
a dose of 400 mg daily for 4 months did not significantly modify plasma concentrations of hepcidin-
25 in a selected group of patients with advanced CKD with primary ESA-hyporesponsiveness and 
who did not have any identifiable cause of ESA-hyporesponsive anaemia. 
 
Anaemia of CKD not only results from deficient production of erythropoietin, but also from reduced 
Fe absorption and availability for erythropoiesis. Fe metabolism is tightly regulated by the Fe-
regulatory hormone hepcidin, which is highly expressed by hepatocytes and at lower levels in other 
tissues including the kidneys. Hepcidin is a negative regulator of Fe absorption by the intestine, and of 
Fe release from macrophages and hepatic stores. It is secreted into the circulation and binds to the Fe 
exporter ferroportin, which is expressed on the surface of enterocytes, macrophages and hepatocytes, 
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causing ferroportin internalisation and degradation. This limits the absorption and release of Fe and 
increases retention in the liver and macrophages 
26, 27
. The balance of a number of positive and 
negative regulators influences hepcidin expression 
28
. Excess Fe and inflammation up-regulate 
hepcidin expression, which in turn, limits the availability of Fe for erythropoiesis and other Fe-
dependent processes. Fe deficiency, anaemia, hypoxia and erythropoietin down-regulate hepcidin 
expression, which subsequently increases Fe bioavailability.  
 
In the pentoxifylline group, the mean adjusted difference for hepcidin-25 concentration tended to be 
lower than in the placebo group. While this difference didn’t reach statistical significance, it is 
nevertheless noteworthy that the adjusted difference between the pentoxifylline group compared to 
the placebo baseline mean translated into a greater than 25% reduction of circulating hepcidin-25 due 
to pentoxifylline, with a lower limit for the 95% CI consistent with a greater than 50% reduction. In 
patients with CKD not on dialysis, hepcidin levels have been found to be approximately 50% lower 
than in haemodialysis patients and in turn associated with 10% higher haemoglobin levels 
29
. Thus, 
the pentoxifylline-associated relative reduction in hepcidin-25 observed in this study is likely to be 
clinically or biologically meaningful.  
 
The results of the main HERO Study showed a significant increase in haemoglobin in patients with 
ESA-hyporesponsive anaemia 
21
, but in the cohort of the hepcidin-25 sub-study a similar tendency for 
higher haemoglobin (pentoxifylline vs. placebo, 112 vs 106g/l) did not reach statistical significance 
due to small sample size. The most likely explanation for the lack of a statistically significant 
difference could be a type 2 statistical error due to the small sample size of patients who consented to 
be included in this sub-study. A relatively large study by in dialysis patients Antunes et al. failed to 
demonstrate an effect of pentoxifylline on either haemoglobin or hepcidin 
30
. However, in this study 
oral pentoxifylline was given at a dose of 400 mg thrice-weekly only, which is exceedingly low; 
furthermore, the study was not placebo-controlled and used a commercial hepcidin-25 assay not 
validated in dialysis patients 
30
, not allowing to draw any definitive conclusions despite larger sample 
size. 
An alternative explanation is that there is no relevant biological effect of pentoxifylline on hepcidin-
25 secretion. The utility of pentoxifylline for the treatment of anaemia in CKD was recently reviewed 
in a meta-analysis of 7 randomized and 4 non-randomized studies 
31
. The pooled analysis of 7 
randomized controlled trials of pentoxifylline versus placebo or standard therapy (299 participants) 
did not show any conclusive evidence that pentoxifylline improved anaemia in CKD patients (mean 
haemoglobin increase 0.12 g/dl, 95% CI -0.22 to 0.47), although it was acknowledged that the 
conclusions that could be drawn from the meta-analysis were limited by an appreciable degree of 
heterogeneity among studies with respect to CKD stage, anaemia severity, intervention duration and 




. A number of the included 
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studies were also limited by small sample size, short follow-up duration, and suboptimal 
methodological quality with either a high or unclear risk of bias.  
A third possible explanation for the observed lack of effect of pentoxifylline on serum hepcidin levels 
in this study may have been that study participants were receiving regular parenteral Fe and their 
mean serum ferritin levels were quite high. Excess Fe and inflammation up-regulate hepcidin 
expression, which in turn, limits the availability of Fe for erythropoiesis and other Fe-dependent 
processes 
28
. Therefore, it is possible that excess Fe from parenteral supplementation might have 
induced up-regulation of hepcidin that could not be offset by the pentoxifylline administered to these 
patients.  
Finally, it is possible that the presumed favourable effect of pentoxifylline on haemoglobin levels may 
be produced by a mechanism other than hepcidin modulation. For instance pentoxifylline through 
improvement of the haemorheological profile and especially its microrheological variables, including 
plasma and whole blood viscosity, red blood cell aggregation and deformability 
32
, which could 





A strength of this study was that it excluded patients if they had evidence of other known causes of 
erythropoietin-hyporesponsive anaemia, including absolute or functional iron deficiency, vitamin B12 
and folate deficiency, elevated aluminium levels, inadequate delivered dialysis dose or 
hyperparathyroidism 
20, 21
. The study was also performed within the context of a multinational, multi-
centre randomized controlled trial, such that the internal and external validity of the findings were 
high. A key strength of the hepcidin-25 sub-study was the fact that it used an optimised and precise 
method for quantifying hepcidin-25 
23, 24
.  
Balanced against these strengths, the study was limited by a relatively small sample size, such that the 
possibility of a type 2 statistical error cannot be discounted. Moreover, the conversion of darbopoetin 
dose to an erythropoietin-equivalent value using the recommended conversion factor of 200:1 is not 
exact and potentially introduced variability, although this was mitigated by the inclusion of ESA class 
in the adaptive randomization allocation algorithm, which balanced erythropoietin and darbopoetin 
use between each group. Finally, there are some potential causes of erythropoietin-hyporesponsive 
anaemia that may have occurred throughout the study period and that may have induced up-regulation 
of hepcidin despite treatment with pentoxifylline. In particular, the occurrence of inflammation, which 
may have been manifest or occult, in relation to clotted synthetic vascular access, dialysis catheter-
related infection, change in the dose of dialysis, periodontal disease, 
34-36
 or underlying malignancy, 
was beyond the control of the baseline randomisation process. 
 
In conclusion, pentoxifylline was not associated with a significant decline in serum hepcidin-25 
concentration in patients with advanced CKD and primary ESA-resistance. However, the extent of the 
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pentoxifylline-associated reduction in hepcidin-25 observed in this study suggests that pentoxifylline 
may be a clinically and biologically meaningful modulator of hepcidin-25 in patients with ESKD. 
Larger prospective studies are required to confirm this association.  
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Table 1:  Demographics and Baseline characteristics by treatment group for the Hepcidin 
sub-study. Results are in mean±SD or numbers (percentage) 
 Placebo (N=13) Pentoxifylline (N=13) 
Age at randomisation (yr) 65.4±16.5 61.8±14.5 
 
Female gender 7 (53.8%) 9 (69.2%) 
 
Ethnicity   
     Caucasian 10 (76.9%) 11 (84.6%) 
     Maori or Pacific Islander 1 (7.7%) 0 
     Asian 1 (7.7%) 2 (15.4%) 
     Other 1 (7.7%) 0 
 
Body Mass Index (kg/m
2
) 30.1±6.9 28.9±6.1 
     Body Mass Index >=30 6 (46.2%) 4 (30.8%) 
 
Smoking Status   
     Never 5 (38.5%) 7 (53.8%) 
     Former 7 (53.8%) 6 (46.2%) 
 
Chronic Kidney Disease Stage   
     Predialysis  1 (7.7%) 0 
     Haemodialysis 12 (92.3%) 13 (100.0%) 
 
Primary cause of end-stage renal failure   
     Diabetes 8 (61.5%) 9 (69.2%) 
     Hypertension 5 (38.5%) 4 (30.8%) 
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Table 2:  Baseline biochemical characteristics by treatment group for the Hepcidin sub-
study. Results are in mean±SD or numbers (percentage) 
 Placebo (N=13) Pentoxifylline (N=13) 
Dosage of ESA (IU/kg/week) 255±87 219±87 
ERI (IU/kg/week/g Hb) 2.4±0.8 2.1±1.0 
Serum Hepcidin-25 (nmol/l) 26.9±15.8 28.6±11.5 
Haemoglobin (g/l) 106±10 105±8 
Serum Ferritin (µg/l) 501±350 599±213 
Transferrin Saturation (%) 26±7 27±11 
Reticulocyte count 61±25 57±27 
C-reactive protein (mg/l) 23±25 20±19 
Vitamin B12 (pmol/l) 425±246 413±157 
Folate (nmol/l) 678±1318 1796±1566 
Parathyroid hormone (pmol/l) 28±24 31±29 
Serum aluminium (mmol/l) 0.38±0.13 0.42±0.08 
Haptoglobin (g/l) 1.4±0.6 1.4±0.6 
 
ESA: erythropoietic stimulatory agents, ERI: erythropoiesis resistance index 
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Table 3:  Primary and secondary outcomes by treatment group for the Hepcidin sub-study 
(mean values and mean differences adjusted for baseline values) 
 
Placebo 
(N = 13) 
Pentoxifylline 




Serum Hepcidin-25 (nmol/L) 30.4 (23.4, 37.4) 22.5 (15.5, 29.5) -7.9 (-17.9, 2.0) 0.114 
Dosage of erythropoietic 
stimulatory agents (IU/kg/week) 
252 (203, 301) 242 (193, 291) -9.9 (-79.7, 59.8) 0.771 
ERI (IU/kg/week/g Hb) 2.38 (1.94, 2.83) 2.22 (1.78, 2.66) -0.17 (-0.46, 0.79) 0.588 
Haemoglobin (g/l) 106 (100, 112) 112 (106, 118) 5.7 (-2.5, 14.0) 0.163 
Serum Ferritin (µg/l) 516 (376, 655) 571 (432, 711) 55.4 (-143, 254.2) 0.570 
Transferrin Saturation (%) 23 (17, 28) 27 (21, 32) 4.04 (-3.92, 11.99) 0.305 
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Figure 1  Serum hepcidin concentration at baseline and 4 months in the pentoxifylline and placebo 
groups. 
 
 
 
 
